Tilray Brands (TLRY) Stock Overview
A lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TLRY Community Fair Values
Create NarrativeSee what 163 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorUS$21.53FV • 64.4% undervalued intrinsic discount
5419.8%Revenue growth p.a.
6.2k
18
0
128
Tilray Brands, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.16 |
| 52 Week High | US$23.20 |
| 52 Week Low | US$3.51 |
| Beta | 2.11 |
| 1 Month Change | -5.95% |
| 3 Month Change | -17.20% |
| 1 Year Change | 35.35% |
| 3 Year Change | -77.76% |
| 5 Year Change | -96.19% |
| Change since IPO | -96.17% |
Recent News & Updates
TLRY: BrewDog Integration And Synergies Will Support Long Term Cash Flow Potential
The analyst price target for Tilray Brands has been reduced by several dollars to $9.00. This reflects analysts' focus on lower future P/E assumptions and execution risks around recent acquisitions, even as they factor in slightly higher revenue growth and profit margin estimates.Tilray Has Strong Synergies, But Sector Remains Weak
Apr 09Recent updates
TLRY: BrewDog Integration And Synergies Will Support Long Term Cash Flow Potential
The analyst price target for Tilray Brands has been reduced by several dollars to $9.00. This reflects analysts' focus on lower future P/E assumptions and execution risks around recent acquisitions, even as they factor in slightly higher revenue growth and profit margin estimates.Tilray Has Strong Synergies, But Sector Remains Weak
Apr 09TLRY: BrewDog Acquisition Execution Will Support Long Term Cash Flow Visibility
Tilray Brands' updated analyst price target framework now points to an implied fair value shift from $19.22 to $20.25. Analysts cite changes to revenue growth assumptions, profit margin expectations, and a higher future P/E multiple following a mix of price target cuts and a recent upgrade on the stock.
TLRY: BrewDog Acquisition Synergies And Schedule III Shift Will Improve Cash Flow Visibility
Analysts have reduced their Tilray Brands price targets to $9.00 from $10.00, reflecting caution regarding the BrewDog asset acquisition and a focus on the company demonstrating it can achieve operational synergies, as well as provide clearer long term visibility into sales and cash flows. Analyst Commentary Recent research updates point to a cautious stance on Tilray Brands, with several Bearish analysts trimming price targets and reiterating more neutral views after both the BrewDog asset acquisition and the latest quarterly results.TLRY: Schedule III Shift And Medical Push Will Improve Cash Flow Visibility
Narrative Update on Tilray Brands The analyst price target for Tilray Brands has been trimmed from $9.25 to $9.00 as analysts factor in a slightly higher discount rate, a lower assumed future P/E, and execution risks and synergy uncertainty around the BrewDog asset acquisition, even though revenue growth and profit margin assumptions remain modestly higher. Analyst Commentary Recent Street research on Tilray Brands has leaned cautious, with multiple bearish analysts trimming price targets and maintaining neutral stances despite some operational positives.TLRY: Rescheduling And Licensing Agreements Will Support Long Term Cash Flow Visibility
Analysts have updated their price target on Tilray Brands to $19.22 from $1.83, reflecting revised assumptions around revenue growth, profit margins, and future P/E following recent coverage initiations and target resets that cited solid Q2 sales with mixed visibility on long-term sales and cash flow. Analyst Commentary Recent Street commentary around Tilray Brands has been mixed, with some firms trimming price targets while keeping ratings neutral.TLRY: Schedule III Rescheduling And Medical Expansion Will Support Cash Flow Visibility
Analysts have trimmed their price targets on Tilray Brands to around $10, reflecting a more cautious stance after recent quarterly results that they viewed as generally in line. Solid international and distribution sales were partly offset by ongoing questions around long term sales visibility and cash flow.TLRY: Schedule III Shift Will Test Medical Expansion And Cash Flow Visibility
Analysts have adjusted their fair value estimate for Tilray Brands from $8.50 to $9.25, citing recent target revisions that reflect more cautious revenue growth assumptions, steady profitability expectations, and an updated outlook for the future price-to-earnings ratio. Analyst Commentary Recent Street research has leaned cautious on Tilray Brands, with bearish analysts trimming price targets and flagging risks around visibility into the company’s longer term financial profile.Lacklustre Performance Is Driving Tilray Brands, Inc.'s (NASDAQ:TLRY) 30% Price Drop
Jan 16
TLRY: Rescheduling To Schedule III Will Expose Medical Expansion Hurdles
Analysts have lifted their fair value estimate for Tilray Brands to $8.50 from $0.60, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that they see as better reflecting the company’s current risk and earnings profile. What's in the News President Trump signed an executive order directing Attorney General Pam Bondi to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act.
TLRY: Reverse Split Will Drive Future Upside As Medical Expansion Advances
Analysts have modestly raised their price target on Tilray Brands to reflect slightly stronger long term revenue growth expectations, even as they factor in significantly compressed profit margins and a sharply higher assumed future price to earnings multiple. What's in the News Tilray Medical outlined a strategic framework for U.S. medical cannabis expansion following federal rescheduling, creating Tilray Medical USA Inc.TLRY: Reverse Split And Medical Expansion Will Drive Future Upside
Analysts have significantly raised their price target on Tilray Brands, lifting fair value expectations from approximately $1.78 to $16.17 per share, citing improved long term earnings visibility and a more favorable valuation multiple outlook. What's in the News Announced a 1 for 10 reverse stock split effective December 2, 2025, aiming to support continued Nasdaq listing and broaden institutional investor eligibility (company announcement).Tilray Brands, Inc. (NASDAQ:TLRY) Looks Inexpensive After Falling 39% But Perhaps Not Attractive Enough
Nov 24TLRY: Federal Policy Shifts Will Drive New U.S. Cannabis Opportunities
Analysts have raised Tilray Brands' price target from $1.50 to $2.00, citing strengthened expectations due to shifting U.S. federal policy toward cannabis and the company's strong market position. Analyst Commentary Analysts have highlighted a range of factors that support an optimistic outlook for Tilray Brands, while also noting certain risks that could affect the company's future performance.TLRY: Progress On U.S. Rescheduling Will Unlock New Market Access
Tilray Brands has received an increased analyst price target from $1.50 to $2.00 per share, reflecting greater optimism because of anticipated regulatory changes and the company’s strong industry positioning. Analyst Commentary Bullish analysts have reacted positively to recent developments affecting Tilray Brands, noting a number of factors that could drive further growth and improve the company’s outlook.Upcoming Federal Policy Shifts Will Open New Opportunities In Cannabis Markets
Analysts have raised their price target on Tilray Brands from $1.50 to $2.00, citing recent shifts in U.S. federal policy toward cannabis and the company's strong positioning to benefit from potential market expansion. Analyst Commentary Following the price target increase, analysts have shared both optimistic and cautious perspectives on Tilray Brands, reflecting on the company's future prospects and potential risks.Expanding European Cannabis Markets Will Unlock Global Wellness Potential
Analysts have raised their price target for Tilray Brands from $1.50 to $2.00, citing anticipated progress in U.S. cannabis policy and Tilray's strong positioning to benefit from broader market access. Analyst Commentary Recent commentary from bullish analysts highlights both the strengths and potential hurdles facing Tilray Brands in the evolving cannabis market.Tilray Brands, Inc.'s (NASDAQ:TLRY) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Oct 03Expanding European Cannabis Markets Will Unlock Global Wellness Potential
Tilray Brands’ consensus price target has increased to $0.983 as analysts cite improved U.S. political momentum toward cannabis rescheduling and Tilray’s strong positioning to benefit from expanding market opportunities. Analyst Commentary Positive political developments, with momentum towards rescheduling marijuana from Schedule I to Schedule III in the U.S., indicating a potential shift in federal cannabis policy.Tilray Brands, Inc. (NASDAQ:TLRY) Surges 66% Yet Its Low P/S Is No Reason For Excitement
Aug 18Tilray Brands, Inc. (NASDAQ:TLRY) Shares Fly 35% But Investors Aren't Buying For Growth
Jul 04
Integrated Operations Will Extend European And US THC Beverage Markets
Strategic initiatives focusing on margin improvements and global expansion efforts could significantly boost profitability and revenue growth.Tilray Brands Could Bounce Big
Apr 28Tilray: Q3 Earnings Could Be The Inflection Point It Needs
Apr 09Lacklustre Performance Is Driving Tilray Brands, Inc.'s (NASDAQ:TLRY) 28% Price Drop
Mar 26Tilray Short Interest Surges Again
Mar 13Shareholder Returns
| TLRY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.7% | 3.3% | 0.8% |
| 1Y | 35.4% | 27.3% | 27.7% |
Return vs Industry: TLRY exceeded the US Pharmaceuticals industry which returned 27.3% over the past year.
Return vs Market: TLRY exceeded the US Market which returned 27.7% over the past year.
Price Volatility
| TLRY volatility | |
|---|---|
| TLRY Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: TLRY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TLRY's weekly volatility has decreased from 19% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 2,842 | Irwin Simon | www.tilray.com |
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products.
Tilray Brands, Inc. Fundamentals Summary
| TLRY fundamental statistics | |
|---|---|
| Market cap | US$734.78m |
| Earnings (TTM) | -US$1.34b |
| Revenue (TTM) | US$858.28m |
0.9x
P/S Ratio-0.5x
P/E RatioIs TLRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLRY income statement (TTM) | |
|---|---|
| Revenue | US$858.28m |
| Cost of Revenue | US$620.72m |
| Gross Profit | US$237.55m |
| Other Expenses | US$1.58b |
| Earnings | -US$1.34b |
Last Reported Earnings
Feb 28, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.27 |
| Gross Margin | 27.68% |
| Net Profit Margin | -156.67% |
| Debt/Equity Ratio | 16.4% |
How did TLRY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 00:28 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2026/02/28 |
| Annual Earnings | 2025/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tilray Brands, Inc. is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |